223560-37-0Relevant articles and documents
Pd(OAc)2-catalyzed one-pot preparation of anthranilates from acyclic unsaturated β-enamino esters
Kishimoto, Ryo,Mikami, Shunya,Okada, Sho,Takabatake, Tetsuhiko,Toyota, Masahiro
, (2020/02/22)
A one-pot synthesis of anthranilates from acyclic unsaturated β-enamino esters with a catalytic amount of Pd(OAc)2 was achieved for the first time. The substrates for the key catalytic reaction were easily prepared from acetoacetate esters and amines, and functionalized anthranilates were obtained in moderate to good chemical yields. A simple assembly of a 13C-labeled anthranilate was demonstrated by applying this protocol. In addition, bioactive NNI-5 was synthesized using this catalytic process.
Removable bidentate directing group assisted-recyclable metal.organic frameworks-catalyzed direct oxidative amination of Sp2 C-H bonds
Tran, Nga T. T.,Tran, Quan H.,Truong, Thanh
, p. 9 - 15 (2015/03/31)
Several Cu-MOFs were showed to be efficient heterogeneous catalysts for ortho-amination of benzoic acid derivative C-H bonds by N-H amines using 8-aminoquinoline as bidentate directing group. The optimal reaction conditions involve the use of Cu-MOFs (25%
2-[(2-Aminobenzyl)sulfinyl]-1-(2-pyridyl)-1,4,5,6- tetrahydrocyclopent[d]imidazoles as a novel class of gastric H+/K+-ATPase inhibitors
Yamada,Yura,Morimoto,Harada,Yamada,Honma,Kinoshita,Sugiura
, p. 596 - 604 (2007/10/03)
Substituted 2-sulfinylimidazoles were synthesized and investigated as potential inhibitors of gastric H+/K+-ATPase. The 4,5-unsubstituted imidazole series 6-11 and the 1,4,5,6-tetrahydrocyclopent[d]imidazole series 12 were found to be potent inhibitors of the acid secretory enzyme H+/K+- ATPase. Structure-activity relationships indicate that the substitution of 2- pyridyl groups at the 1-position of the imidazole moiety combined with (2- aminobenzyl)sulfinyl groups at the 2-position leads to highly active compounds with a favorable chemical stability. Other substitution patterns in the imidazole moiety result in reducing biological activities. 2-[(2- Aminobenzyl)sulfinyl]-1-[2-(3-methylpyridyl)]-1,4,5,6- tetrahydrocyclopent[d]imidazole (12h, T-776) was selected for further development as a potential clinical candidate. Extensive study on the acid degradation of 12h indicates a mechanism of action different from that of omeprazole, the first H+/K+-ATPase inhibitor introduced to the market.